So you see what’s possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.

Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.Forecasts and other information explaining lucrative possibilities for treatments

Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.Futures of medicines stopping and preventing haemorrhaging – data to help your work

There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.

The report shows you issues and events affecting that industry from 2014, including these:– Advances in understanding haemostasis and coagulation aiding science and product development– Needle-free drug delivery and other innovations– Synthetic purification processes and other novel techniques for making biologics and biosimilars– Long-acting clotting factor therapy and recombinant coagulation factors– Use of prophylactic schedules (prophylaxis) increasing– Regulators, pricing, and other challenges – approvals, costs, and concerns.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry and affects results.Companies and overall 2017 market value – find outlook for success

What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.

So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps

In particular, our new investigation gives you these advantages:– Revenues there to 2024 at world level, for 4 submarkets, and 15 products – assess outlooks for production, marketing, and sales– Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia – examine developed and developing countries for potential revenues– Prospects for established competitors, emerging companies, and new entrants – investigate portfolios, results, strategies, developmental activities, and successes.

3.1 The World Pharmaceutical Market for Bleeding Disorders in 20123.2 The Bleeding Disorders Pharmaceutical Market: An Overarching Revenue Forecast 2014-20243.3 The Pharmaceutical Market by Bleeding Disorder: Comparison of Revenue and Market Share, 2018 and 20243.4 The World Pharmaceutical Market for Bleeding Disorders by Therapeutic Subclass: Grouped Revenue Forecasts 2014-20243.5 Haemophilia A Accounted for Almost 70% of the Market in 20123.6 Haemophilia B Will See Increasing Prominence in the Bleeding Disorders Market3.7 Thrombocytopenia3.8 Other Coagulation Factor Deficiencies3.9 Summary of the Research and Analyses

4. Leading Drugs of the Market for Treating Bleeding Disorders, 2014-2024

4.1 The Leading Drugs for the Treatment of Bleeding Disorders in 20124.2 Leading Bleeding Disorder Drugs: Comparison of Revenue and Market Share, 2018 and 20244.3 Leading Bleeding Disorder Drugs: A Grouped Revenue Forecast, 2014-20244.4 Advate Will Continue to Dominate the Market4.5 NovoSeven: Patent Protection Has Expired, But Revenue Generation Remains Strong4.6 Kogenate: Needle-Free Delivery Makes it an Attractive Option for Patients4.7 BeneFIX Faces Competition in 2013 – How Will This Affect Revenue?4.8 FEIBA: The Original Treatment for Disease with Inhibitors4.9 ReFacto/ Xyntha: Produced Using an Entirely Synthetic Purification Process4.10 Helixate: Marketing Agreement With Bayer Extends Until 20174.11 Nplate: The Leading Product for Thrombocytopenia in 20124.12 Alphanate: A Staple Treatment for Bleeding Disorders Since 19784.13 Promacta Competes With Nplate, But Which Will Prove Most Successful?4.14 Promising Compounds in the Developmental Pipeline4.14.1 Rixubis: The First Recombinant FIX Treatment Factor for Routine Prophylaxis in Haemophilia B4.14.2 Eloctate: The First Long-Acting Clotting Factor Therapy for Haemophilia A?4.14.3 Alprolix: The First Long-Acting Clotting Factor Treatment for Haemophilia B?4.14.4 N8-GP: Novo Nordisk’s Long Acting Compound for the Treatment of Haemophilia A4.14.5 N9-GP: Novo Nordisk’s Long-Acting Treatment for Haemophilia B

5. The Leading National Pharmaceutical Markets for Bleeding Disorders, 2014-2024

5.1 The Leading National Markets for Bleeding Disorders: The US Dominates in 20125.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 20245.3 Leading National Pharmaceutical Markets for Bleeding Disorders: Grouped Revenue Forecasts, 2014-20245.4 The US Will Continue to Dominate the Bleeding Disorders Market Throughout the Forecast Period5.5 The EU5: What Prospects There?5.5.1 Germany Will Remain the Largest of the EU5 Markets5.5.2 France: Increasing Uptake of Prophylactic Therapy Will Drive Growth5.5.3 Italy: The 3rd Largest Market of the EU55.5.4 The UK: Well Developed Infrastructure for the Treatment of Bleeding Disorders5.5.5 Spain: Use of Recombinant Coagulation Factors is Relatively Low at Present5.6 Japan: Use of Prophylactic Treatment is Lower Than That of the Western World5.7 China: A Growing Domestic Bleeding Disorders Pharmaceutical Market5.8 Brazil: Baxter Will Be the Exclusive Provider of Recombinant Therapy for the Next 10 Years5.9 India: 90% of Patients Are Unable to Afford Treatment Costs5.10 Russia: Treatment Levels Per Capita Are High

6. Bleeding Disorders: R&D Pipelines, 2013

6.1 The R&D Pipeline for Bleeding Disorders: An Overview6.2 Four Candidates Are In Pre-Registration6.2.1 Novo Nordisk’s NovoEight6.2.2 Novo Nordisk’s NovoThirteen: Denied Approval by the FDA for the Second Time; Will It Be Third Time Lucky?6.2.3 Biogen Idec’s Eloctate: The First Long-Acting Treatment for Haemophilia A?6.2.4 Biogen Idec’s Alprolix: The First Long-Acting Treatment for Haemophilia B?6.3 The Phase III Development Pipeline: Novo Nordisk Has a Strong Presence6.3.1 Novo Nordisk’s N8-GP and N9-GP: Second in Class Treatments?6.3.2 Baxter’s rFVIIa BI6.3.3 Octapharma’s Human-cl rhFVIII6.4 The Phase II/III Development Pipeline: An Abundance of Haemophilia A Treatments6.4.1 Baxter’s BAX855: Another Long-Acting Haemophilia A Treatment6.4.2 Baxter has Purchased OBI-1 from Inspiration Biopharmaceuticals6.5 The Phase I/II Development Pipeline: Gene Therapy for Haemophilia B6.6 The Phase I Development Pipeline: Offerings from Novo Nordisk and Pfizer6.6.1 Novo Nordisk’s mAb20216.6.2 Pfizer’s PF-05280602

7. Leading Companies of the Bleeding Disorders Pharmaceutical Market

7.1 The Leading Companies of the Bleeding Disorders Pharmaceutical Market7.2 Baxter Accounted for Over 30% of the Bleeding Disorders Market in 2012, But Will It Remain Market Leader?7.3 Novo Nordisk: Demonstrating Commitment to Treating Bleeding Disorders7.4 Bayer: A Limited Product Portfolio?7.5 Pfizer: Declining Market Share During the Forecast Period?7.6 CSL Behring Has the largest Portfolio of Bleeding Disorder Drugs7.7 Grifols Will Have a Declining Market Share7.8 Amgen: Single Stake in the Bleeding Disorders Market7.9 Octapharma: Branching Into Recombinant Coagulation Factors7.10 GSK: Bleeding Disorders Are Not a Main Therapeutic Focus7.11 Biogen Idec: Market Entry Anticipated in 2014

8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 20138.1.1 Treatment of Bleeding is Essential8.1.2 The Threat of Generic/Biosimilar Competition is Low8.1.3 Advances in Technology Have Improved Treatment Options8.1.4 A Small Patient Population Ultimately Restricts the Market8.1.5 Emerging National Markets: Patients Often Having Little Access to Treatments8.1.6 High Barriers to Market Entry8.1.7 The Burden of Prophylactic Therapy8.2 The Opportunities and Threats Facing the Market, 2014-20248.2.1 Low Switch Rate Among Patients Receiving Treatment for Bleeding Disorders: An Opportunity and a Threat8.2.2 Demand for Treatment in the Emerging Markets is Increases, But Are Recombinant Therapies Too Expensive?8.2.3 High Barriers to Market Entry Will Limit Competition, But Also Limit Development8.3 Social, Technological, Economic and Political Forces Influencing the Bleeding Disorders Pharmaceutical Market, 2014-20248.3.1 Social Factors8.3.2 Technological Factors8.3.3 Economic Factors8.3.4 Political Factors

9. Research Interview

9.1 Interview With Dr Kamran Kamyar, M.D., Medical Manager, AryoGen Biopharma9.1.1 On the State of the Current Market9.1.2 On AryoGen’s Presence in the Market9.1.3 On Important Developments in the Industry

10. Conclusions from Our Study

10.1 The World Pharmaceutical Market for Bleeding Disorders, 2014-202410.2 Bleeding Disorders: Leading Products on the Market, 2014-202410.3 Leading National Markets for the Bleeding Disorder Pharmaceutical Industry, 2014-202410.4 Trends in that Industry and Market10.4.1 Bleeding Disorders Are Serious Conditions Requiring Frequent Drug Treatment10.4.2 The Demand for Drug Treatment Is Increasing10.4.3 The R&D Pipeline is Well Stocked, But What Does This Mean for the Industry?